LONDON, March 18, 2013 /PRNewswire/ --
The Cure Parkinson's Trust, a charity founded by four people with Parkinson's disease, which is dedicated to finding, facilitating and funding work towards a cure, today welcomes Kenneth Mulvany to the charity as Chairman.
Ken Mulvany is an entrepreneur and healthcare industry veteran and brings more than 15 years of business leadership and experience to The Cure Parkinson's Trust. Ken was previously CEO of Proximagen, a UK-based biotech company committed to delivering novel drugs and innovative new treatments for Central Nervous System (CNS) disorders. Proximagen was acquired in August 2012 by Upsher-Smith Laboratories, Inc. in the US where this pipeline of CNS programmes continues to be advanced.
Sir Richard Nichols, former Lord Mayor of London, and co-founder of the charity, has stepped down as Chairman after eight successful and supportive years during which the Charity has grown significantly and firmly cemented its vision of providing support towards finding a cure for Parkinson's.Tom Isaacs, Co-founder and President of The Cure Parkinson's Trust, said: "We welcome Ken Mulvany to the Charity and look forward to working with him as he puts a new perspective on problem solving and bringing fresh ideas to moving potential new therapies forward to halt, and reverse Parkinson's. Due to his entrepreneurial vision and industry background, we believe Ken is going to be a strong follow-on Chairman to Sir Richard. He will guide us in fostering new and effective relationships with industry that can help us fulfil our vision to fund innovative research and find a cure for Parkinson's. On behalf of the charity I want to thank Sir Richard Nichols for his inspirational and dedicated chairmanship." The newly appointed Chairman of The Cure Parkinson's Trust, Ken Mulvany, said: "I have known Tom and the team at The Cure Parkinson's Trust for many years now and thoroughly admire the work the team plus all of the fantastic supporters have been doing to fulfil the charity's vision. Their success has enabled the charity to fund innovative research and inspirational scientists whose work is starting to make a difference as trials into new treatments get underway. I very much hope I can bring connections to the pharmaceutical industry and additional support that will help to advance potential cures for Parkinson's." Sir Richard Nichols, former Chairman of The Cure Parkinson's Trust, added: "Since we founded The Cure Parkinson's Trust in 2005, we have seen so much change in the field of Parkinson's research. It is very encouraging to know that we are on the cusp of major breakthroughs in Parkinson's, and new areas are being investigated fruitfully. It has been a privilege to lead this dynamic organisation since its inception, and I am delighted that Ken has the vision and determination to enable the Trust to reach its goal of finding cures for Parkinson's." Notes for Editors: